![John Montana](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John Montana
Directeur Général chez Oxitope Pharma BV
Postes actifs de John Montana
Sociétés | Poste | Début | Fin |
---|---|---|---|
Metrion Biosciences Ltd.
![]() Metrion Biosciences Ltd. BiotechnologyHealth Technology Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016. | Directeur/Membre du Conseil | 09/02/2021 | - |
Oxitope Pharma BV
![]() Oxitope Pharma BV Pharmaceuticals: MajorHealth Technology Oxitope Pharma BV is a Dutch pharmaceutical start-up founded in 2020 that focuses on discovering and developing medicine for the treatment of inflammatory and cardiovascular diseases caused by oxidative stress. The company is based in Naarden, Netherlands. The Dutch company takes a different approach to the diagnosis and treatment of these diseases by preventing, halting, or reversing acute and chronic diseases driven by oxidized phospholipids. Oxitope Pharma's goal is to enable people to live long and healthy lives. The CEO is John Montana. | Directeur/Membre du Conseil | - | - |
Directeur Général | - | - | |
Directeur des opérations | 01/04/2020 | - | |
Forbion Capital Partners Management Holding BV
![]() Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Investor | 01/01/2020 | - |
Historique de carrière de John Montana
Anciens postes connus de John Montana
Sociétés | Poste | Début | Fin |
---|---|---|---|
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Corporate Officer/Principal | - | - |
Glaxo, Inc. | Corporate Officer/Principal | - | - |
Paradigm Therapeutics Ltd.
![]() Paradigm Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK. | Corporate Officer/Principal | - | - |
Chiroscience Group Plc | Corporate Officer/Principal | - | - |
Pulmagen Therapeutics (Synergy) Ltd.
![]() Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Directeur/Membre du Conseil | 01/01/2005 | - |
Directeur Technique/Scientifique/R&D | 01/01/2005 | - |
Formation de John Montana
The University of Manchester | Undergraduate Degree |
University of East Anglia | Doctorate Degree |
Statistiques
Internationale
Royaume-Uni | 6 |
Canada | 2 |
Etats-Unis | 2 |
Opérationnelle
Corporate Officer/Principal | 4 |
Director/Board Member | 3 |
Chief Tech/Sci/R&D Officer | 1 |
Sectorielle
Commercial Services | 4 |
Health Technology | 4 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Commercial Services |
Entreprise privées | 7 |
---|---|
Pulmagen Therapeutics (Synergy) Ltd.
![]() Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Commercial Services |
Paradigm Therapeutics Ltd.
![]() Paradigm Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK. | Health Technology |
Chiroscience Group Plc | Commercial Services |
Glaxo, Inc. | |
Metrion Biosciences Ltd.
![]() Metrion Biosciences Ltd. BiotechnologyHealth Technology Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016. | Health Technology |
Oxitope Pharma BV
![]() Oxitope Pharma BV Pharmaceuticals: MajorHealth Technology Oxitope Pharma BV is a Dutch pharmaceutical start-up founded in 2020 that focuses on discovering and developing medicine for the treatment of inflammatory and cardiovascular diseases caused by oxidative stress. The company is based in Naarden, Netherlands. The Dutch company takes a different approach to the diagnosis and treatment of these diseases by preventing, halting, or reversing acute and chronic diseases driven by oxidized phospholipids. Oxitope Pharma's goal is to enable people to live long and healthy lives. The CEO is John Montana. | Health Technology |
Forbion Capital Partners Management Holding BV
![]() Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
- Bourse
- Insiders
- John Montana
- Expérience